Delamanid

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.5. Antituberculosis medicines

EMLc | ATC codes: J04AK06

Indication	Multi-drug resistant Mycobacterium tuberculosis ICD11 code: MG52.00
INN	Delamanid
Medicine type	Chemical agent
List type	Core
Additional notes	Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.
Formulations	**Oral > Solid > dispersible tablet:** 25 mg (EMLc) **Oral > Solid > tablet:** 50 mg
EML status history	First added in 2015 (TRS 994) Changed in 2017 (TRS 1006) Changed in 2019 (TRS 1021) Changed in 2021 (TRS 1035) Changed in 2023 (TRS 1049) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Read more about patents.
Wikipedia	Delamanid
DrugBank	Delamanid

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.